Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.28) by 12.06 percent. This is a 8.87 percent increase over losses of $(1.24) per share from the same period last year.
Jasper Therapeutics (NASDAQ:JSPR) reported quarterly losses of $(1.13) per share which beat the analyst consensus estimate of $(1.28) by 12.06 percent. This is a 8.87 percent increase over losses of $(1.24) per share from the same period last year.
Comments